08:00 , Mar 16, 1998 |  BioCentury  |  Finance

Glaxo thinks ROI

Glaxo thinks ROI Glaxo's planned purchase of $50 million in Affymetrix preferred stock is a pure investment play, according to both sides of the deal (B12) . Glaxo already owns 33 percent of AFFX through...